this is actually based on actual hss data. so, for example, in the top category there. antidiabetic agents, the generic version called extended relief. that had an average cost for hss of over $700 per 30-day supply. another version of that same medication cost over $4,000 per prescription. and then the brand version of that medication, called gl lumetzglumetza cost $6,500. if you look at the medication by population that only cost $7 per prescription. so we really want to drivualization towardif lent medication but at a lower cost. >> we've had these discussions in the past over drugs and many times the members would say that i guess there are different binders and many have different drugs. they claim they are the same but they are not, i guess. >> we are just following the fda

this is actually based on actual hss data. so, for example, in the top cary

medicals and 15 drugs were impacted and were being taken by hss members which was 0.9% of types of medications filled. so when our analyst evaluated the data and made the shift assumptions for the hss plan, the estimated savings to hss is about 360,000 but that really depends on changes in utilization, shifts and so forth. so that was just the estimation based on what the analyst predicted would be marketplace changes for the marketplace. >> can i ask a question? >> randy scott: shae. please. >> you look at this -- what i'm take away from the design of this particular slide -- it doesn't really effect very many people and not very many drugs. so it probably doesn't mean anything. what i see from this, a small handful of people for whatever reason are being predescribed these drug drugs and they may have unique circumstances that require them is. there's a pattern here for the most part people are driving toward lower cost drugs but as we know in medicine there are unique circumstances. every human being is different. so i guess given that there isn't a lot of cost here, that -- this is just a small sliver it. lead me to suspect that we are